drug
(insulin glargine + lixisenatide)
Marketedupdated 5mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugSOLIQUA 100/3324 co-mentions · 12 sources
- tagApproval24 co-mentions · 12 sources
- druginsulin glargine LA12 co-mentions · 12 sources
- drugAbasaglar12 co-mentions · 12 sources
- druginsulin12 co-mentions · 12 sources
- drugToujeo LA12 co-mentions · 12 sources
- company$SNYSanofi12 co-mentions · 12 sources
- company$SNYNFSanofi12 co-mentions · 12 sources
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
News(1)
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.fiercebiotech · 1mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that